Thomas Beckers

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

Wilko Weichert, A.-E. Roske, Volker Gekeler et al. · British Journal of Cancer · 2008 · 474 citations · Full text

Histone Modifications, Chromatin, Hdac Inhibitors +15

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases <i>In vitro</i> and <i>In vivo</i>

Wilko Weichert, A.-E. Roske, Silvia Niesporek et al. · Clinical Cancer Research · 2008 · 370 citations

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

Wilko Weichert, A.-E. Roske, Volker Gekeler et al. · The Lancet Oncology · 2008 · 362 citations

Histone Modifications, Chromatin, Gastrointestinal Oncology +12

Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group

Thomas Beckers, Carmen Burkhardt, H. Wieland et al. · International Journal of Cancer · 2007 · 194 citations · Full text

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

Florian Fritzsche, Wilko Weichert, A.-E. Roske et al. · BMC Cancer · 2008 · 164 citations · Full text